JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1986; 7:1363-1369
© 1986 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giardina, E.
Right arrow Articles by Louie, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giardina, E.
Right arrow Articles by Louie, M

The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations

EG Giardina, T Barnard, L Johnson, AL Saroff, JT Bigger Jr, and M Louie

The effect of nortriptyline against ventricular arrhythmias was determined in 16 cardiac patients with 30 or more ventricular premature depolarizations per hour. Nortriptyline was administered orally, 0.5 mg/kg body weight per day, and increased by 0.5 mg/kg per day every third day until ventricular premature depolarizations were suppressed (greater than or equal to 80%), adverse effects occurred or a total daily dose of 3.5 mg/kg per day was given. Each patient had daily 24 hour continuous electrocardiograms, 12 lead standard electrocardiograms and physical examination; blood pressure was measured in the supine and standing position four times a day. Each patient also had radionuclide angiography at rest to measure ejection fraction before and at the effective or maximal dose. Thirteen patients (81%) had an antiarrhythmic response and 11 met the study criterion of at least 80% improvement. Doses ranged from 50 to 200 mg/day (mean 111 +/- 45), steady state plasma concentration ranged from 46 to 410 ng/ml (mean 153 +/- 96) and half-life of elimination of nortriptyline was 4 to 22 hours (mean 13 +/- 4). Administration of nortriptyline did not depress mean ejection fraction (before 42 +/- 12%, after 41 +/- 12%); it was associated with an orthostatic decrease in systolic blood pressure (mean -13 +/- 13 mm Hg). Nortriptyline is an effective antiarrhythmic agent which may be given twice a day even in patients with impaired ventricular function.


This article has been cited by other articles:


Home page
 Eur Heart JHome page
M. J. Zellweger, R. H. Osterwalder, W. Langewitz, and M. E. Pfisterer
Coronary artery disease and depression
Eur. Heart J., January 1, 2004; 25(1): 3 - 9.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. P. Roose, F. Laghrissi-Thode, J. S. Kennedy, J. C. Nelson, J. T. Bigger Jr, B. G. Pollock, A. Gaffney, M. Narayan, M. S. Finkel, J. McCafferty, et al.
Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease
JAMA, January 28, 1998; 279(4): 287 - 291.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
D. Gitlin
The Intensivists' Exposure to Tricyclic Antidepressants
J Intensive Care Med, March 1, 1990; 5(2): 57 - 58.
[PDF]

Home page
 J Intensive Care MedHome page
G. W. Dec and T. A. Stern
Tricyclic Antidepressants in the Intensive Care Unit
J Intensive Care Med, March 1, 1990; 5(2): 69 - 81.
[Abstract] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1986 by the American College of Cardiology Foundation.